STERIS announced that revenue from continuing operations for the 3 months ended June 30, 2025 was $1,391.1 million, an increase of 9% compared with $1,279.5 million in the prior-year period. Diluted earnings per share from continuing operations was $1.79, and adjusted earnings per share was $2.34.

1. 01

   STERIS announced that revenue from continuing operations for the 3 months ended June 30, 2025 was $1,391.1 million, an increase of 9% compared with $1,279.5 million in the prior-year period. Diluted earnings per share from continuing operations was $1.79, and adjusted earnings per share was $2.34.

2. 02

   The company said Healthcare revenue for Q1 was $974.7 million, AST revenue was $281.2 million, and Life Sciences revenue was $135.2 million. Segment operating income was $235.5 million, $136.7 million and $58.7 million, respectively.

3. 03

   STERIS said net cash provided by operations for Q1 was $420.0 million, compared with $303.7 million in the prior-year period. Free cash flow was $326.5 million, compared with $195.7 million in the prior-year period.

4. 04

   The company updated its fiscal 2026 outlook for as reported revenue growth to 8-9%, compared with prior expectations of 6-7%. Karen Burton will become Senior Vice President and Chief Financial Officer effective August 18, 2025.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.